Therese Bittermann1,2, Peter L Abt3, Kim M Olthoff3, Navpreet Kaur4, Julie K Heimbach5, Juliet Emamaullee4. 1. Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA. 2. Division of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA. 3. Division of Transplant Surgery, University of Pennsylvania, Philadelphia, PA. 4. Department of Surgery, University of Southern California, Los Angeles, CA. 5. Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN.
Abstract
BACKGROUND: Survival after living donor liver transplantation (LDLT) in the United States is excellent. However, the significance of pretransplant kidney disease on outcomes in this population is poorly understood. METHODS: This was a retrospective cohort study of 2806 LDLT recipients nationally between January 2010 and June 2020. Recipients with estimated glomerular filtration rate <40 mL/min/1.73 m2 (eGFR-low) or requiring dialysis were compared. Multivariable survival analyses evaluated (1) eGFR-low as a predictor of post-LDLT survival and (2) the survival of LDLT versus deceased donor liver transplant (DDLT) alone with eGFR-low. RESULTS: From 2010 to 2020, 140 (5.0%) patients had eGFR-low and 18 (0.6%) required dialysis pre-LDLT. The number of LDLTs requiring dialysis between 2017 and 2020 outnumbered the prior 7 y. Overall LDLT experience was greater at centers performing LDLT in recipients with renal dysfunction (P < 0.001). LDLT recipients with eGFR-low had longstanding renal dysfunction: mean eGFR 3-6 mo before LDLT 42.7 (±15.1) mL/min/1.73 m2. Nearly half (5/12) of eGFR-low recipients with active kidney transplant (KT) listing at LDLT experienced renal recovery. Five patients underwent early KT after LDLT via the new "safety net" policy. Unadjusted survival after LDLT was worse with eGFR-low (hazard ratio 2.12 versus eGFR ≥40 mL/min/1.73 m2; 95% confidence interval, 1.47-3.05; P < 0.001), but no longer so when accounting for mean eGFR 3-6 mo pre-LDLT (hazard ratio, 1.27; 95% confidence interval, 0.82-1.95; P = 0.3). The adjusted survival of patients with eGFR-low receiving LDLT versus deceased donor liver transplant alone was not different (P = 0.08). CONCLUSIONS: Overall, outcomes after LDLT with advanced renal dysfunction are acceptable. These findings are relevant given the recent "safety net" KT policy.
BACKGROUND: Survival after living donor liver transplantation (LDLT) in the United States is excellent. However, the significance of pretransplant kidney disease on outcomes in this population is poorly understood. METHODS: This was a retrospective cohort study of 2806 LDLT recipients nationally between January 2010 and June 2020. Recipients with estimated glomerular filtration rate <40 mL/min/1.73 m2 (eGFR-low) or requiring dialysis were compared. Multivariable survival analyses evaluated (1) eGFR-low as a predictor of post-LDLT survival and (2) the survival of LDLT versus deceased donor liver transplant (DDLT) alone with eGFR-low. RESULTS: From 2010 to 2020, 140 (5.0%) patients had eGFR-low and 18 (0.6%) required dialysis pre-LDLT. The number of LDLTs requiring dialysis between 2017 and 2020 outnumbered the prior 7 y. Overall LDLT experience was greater at centers performing LDLT in recipients with renal dysfunction (P < 0.001). LDLT recipients with eGFR-low had longstanding renal dysfunction: mean eGFR 3-6 mo before LDLT 42.7 (±15.1) mL/min/1.73 m2. Nearly half (5/12) of eGFR-low recipients with active kidney transplant (KT) listing at LDLT experienced renal recovery. Five patients underwent early KT after LDLT via the new "safety net" policy. Unadjusted survival after LDLT was worse with eGFR-low (hazard ratio 2.12 versus eGFR ≥40 mL/min/1.73 m2; 95% confidence interval, 1.47-3.05; P < 0.001), but no longer so when accounting for mean eGFR 3-6 mo pre-LDLT (hazard ratio, 1.27; 95% confidence interval, 0.82-1.95; P = 0.3). The adjusted survival of patients with eGFR-low receiving LDLT versus deceased donor liver transplant alone was not different (P = 0.08). CONCLUSIONS: Overall, outcomes after LDLT with advanced renal dysfunction are acceptable. These findings are relevant given the recent "safety net" KT policy.
Authors: B Samstein; A R Smith; C E Freise; M A Zimmerman; T Baker; K M Olthoff; R A Fisher; R M Merion Journal: Am J Transplant Date: 2015-10-13 Impact factor: 8.086
Authors: N Goldaracena; M Marquez; N Selzner; V N Spetzler; M S Cattral; P D Greig; L Lilly; I D McGilvray; G A Levy; A Ghanekar; E L Renner; D R Grant; M Selzner Journal: Am J Transplant Date: 2014-10-02 Impact factor: 8.086
Authors: Carl L Berg; Robert M Merion; Tempie H Shearon; Kim M Olthoff; Robert S Brown; Talia B Baker; Gregory T Everson; Johnny C Hong; Norah Terrault; Paul H Hayashi; Robert A Fisher; James E Everhart Journal: Hepatology Date: 2011-10 Impact factor: 17.425
Authors: Jung Pyo Lee; Hyuk Yong Kwon; Ji In Park; Nam-Joon Yi; Kyung-Suk Suh; Hae Won Lee; Myounghee Kim; Yun Kyu Oh; Chun Soo Lim; Yon Su Kim Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: Xingxing S Cheng; W Ray Kim; Jane C Tan; Glenn M Chertow; Jeremy Goldhaber-Fiebert Journal: Transplantation Date: 2018-05 Impact factor: 4.939
Authors: Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked Journal: Ann Surg Date: 2015-09 Impact factor: 12.969